SG Americas Securities LLC Purchases Shares of 50,058 Ralliant Corporation $RAL

SG Americas Securities LLC purchased a new stake in shares of Ralliant Corporation (NYSE:RAL) in the third quarter, HoldingsChannel reports. The institutional investor purchased 50,058 shares of the company’s stock, valued at approximately $2,189,000.

Other institutional investors also recently modified their holdings of the company. NORTHSTAR ASSET MANAGEMENT Co bought a new stake in Ralliant during the third quarter valued at approximately $225,000. Chicago Capital LLC purchased a new stake in shares of Ralliant during the 3rd quarter valued at $220,000. Alpha Omega Wealth Management LLC lifted its holdings in shares of Ralliant by 27.9% during the 3rd quarter. Alpha Omega Wealth Management LLC now owns 5,629 shares of the company’s stock worth $246,000 after acquiring an additional 1,228 shares during the last quarter. GraniteShares Advisors LLC grew its position in Ralliant by 156.3% in the third quarter. GraniteShares Advisors LLC now owns 6,278 shares of the company’s stock worth $275,000 after acquiring an additional 3,829 shares in the last quarter. Finally, Olstein Capital Management L.P. grew its position in Ralliant by 433.8% in the third quarter. Olstein Capital Management L.P. now owns 145,000 shares of the company’s stock worth $6,341,000 after acquiring an additional 117,834 shares in the last quarter.

Wall Street Analyst Weigh In

RAL has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Truist Financial began coverage on Ralliant in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 target price for the company. Oppenheimer lifted their price target on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Barclays upped their price objective on shares of Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, January 7th. Finally, Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $58.00.

Ralliant Stock Performance

NYSE:RAL opened at $52.25 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49. Ralliant Corporation has a fifty-two week low of $40.70 and a fifty-two week high of $55.08. The company’s 50 day moving average is $49.68. The stock has a market capitalization of $5.89 billion and a price-to-earnings ratio of 41.14.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.02. The firm had revenue of $529.10 million for the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s dividend payout ratio (DPR) is presently 15.75%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.